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study was shown to be superior to those of Celecoxib for treating active
osteoarthritis.
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A PILOT STUDY OF THE USE OF A TRUFIT PLUG FOR CARTILAGE REPAIR
IN THE KNEE AND HOW TO DEAL WITH EARLY CLINICAL FAILURES?
A.A. Dhollander, K. Liekens, F. Almqvist, R. Verdonk, S. Lambrecht,
D. Elewaut, G. Verbruggen, P.C. Verdonk. Ghent Univ., Ghent, Belgium
Purpose: The purpose of this pilot study is to present our short-term
experience with the TruFit plug (Smith & Nephew, Andover, MA) for
cartilage repair in the knee and to discuss our approach to treat early
clinical failures.
Methods: Twenty patients were consecutively treated for their cartilage
lesion with this plug technique. These patients were prospectively
clinically evaluated at 6 and 12 months of follow-up. Magnetic resonance
imaging (MRI) was used for morphological analysis of the cartilage repair.
Biopsy samples were taken from 3 cases during revision surgery, allowing
histological assesment of the repair tissue.
Results: The short-term clinical and MRI outcome of this pilot study
are mediocre. No signs of deterioration of the repair tissue were
observed. Three of the 15 patients (20.0%) displayed persistent or even
more clinical symptoms after insertion of the plug. These patients
were considered as failures and therefore eligible for revision surgery.
During revision surgery the repair tissue was carefully removed. The
remaining osteochondral defect was ﬁlled with autologous bone grafts.
Immediate and persistent relieve of symptoms was observed in all
3 patients. Histological assessment of biopsy specimens taken during
revision surgery of these 3 patients revealed ﬁbrous vascularized repair
tissue with the presence of foreign-body giant cells.
Conclusion: The overall short term clinical and MRI outcome of a
TruFit plug for cartilage repair in the knee is mediocre. In this pilot
study a modest clinical improvement became apparent at 12 months
of follow-up. MRI data showed no deterioration of the repair tissue.
Remarkably, 3 of the 15 patients (20%) had persistent clinical symptoms
after surgery. These patients were succesfully treated with the removal
of the osteochondral plug remnants and the application of autologous
bone grafts. Longer follow-up studies and randomised controlled trials
are mandatory to conﬁrm the ﬁndings of this pilot study.
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MID-TERM RESULTS OF THE TREATMENT OF CARTILAGE DEFECTS
IN THE KNEE USING ALGINATE BEADS CONTAINING HUMAN MATURE
ALLOGENIC CHONDROCYTES
A.A. Dhollander, P.C. Verdonk, R. Verdonk, S. Lambrecht, D. Elewaut,
G. Verbruggen, F. Almqvist. Ghent Univ., Ghent, Belgium
Purpose: The purpose of this paper was to present our mid-term
experience with the implantation of alginate beads containing human
mature allogenic chondrocytes for the treatment of cartilage lesions in
the knee.
Methods: A biodegradable, alginate-based biocompatible scaffold
containing human mature allogenic chondrocytes was used for cartilage
lesions in the knee. Twenty-one patients were clinically prospectively
evaluated with use of the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) and a Visual Analogue Scale (VAS). The
mean follow-up time was 6.3 years (5–8 years). MRI data were analyzed
based on the MOCART (Magnetic Resonance Observation of Cartilage
Repair Tissue) system, allowing morphological assessment of the repair
tissue. MRI images were taken at one year of follow-up and at a mean
follow-up of 6.1 years (5–7 years).
Results: During the follow-up period the WOMAC and VAS scores
improved signiﬁcantly. No signs of clinical deterioration or adverse
reactions to the alginate beads/allogenic chondrocyte implantation were
observed. Four failures occured during the follow-up period in this study
(19.05%). The MOCART scoring methods indicated that the condition of
the repair tissue deteriorated on MRI.
Conclusions: This investigation provided useful information on the
efﬁcacy of this new treatment in chondral lesions of the knee. The
mid-term clinical outcome of the presented technique was promising.
However, these results were not conﬁrmed by the MRI ﬁndings.
Moreover, the MRI data indicated a deterioration of the repair tissue.
These results inspire us to search for further improvements of this
technique.
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DULOXETINE AS TREATMENT FOR KNEE PAIN IN PATIENTS
WITH OSTEOARTHRITIS WHO REGULARLY USE NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS (NSAIDs): A POST HOC ANALYSIS OF
TWO RANDOMIZED, PLACEBO-CONTROLLED TRIALS
M.C. Hochberg1, L. Peng2, J. Ahl2, S. Zhang3, V. Skljarevski3, P. Gaynor2,
M.M. Wohlreich2. 1Univ. of Maryland Sch. of Med., Baltimore, MD, USA;
2Lilly USA, LLC, Indianapolis, IN, USA; 3Lilly Res. Lab., Eli Lilly and Company,
Indianapolis, IN, USA
Purpose: To examine whether treatment with duloxetine has similar
efﬁcacy in patients with symptomatic knee osteoarthritis (OA) who
regularly use NSAIDs as compared with those who do not.
Methods: We conducted a post hoc analysis of data from 2 randomized,
placebo-controlled trials of duloxetine in patients with symptomatic
knee OA. In each trial, patients were randomized to 13 weeks of
treatment with duloxetine 60–120mg once daily or placebo, and
stratiﬁed according to concomitant NSAID use at baseline. NSAID users
were identiﬁed as those patients who were taking a therapeutic dose
of NSAID or acetaminophen for ≥14 days per month for 3 months
immediately preceding the study. Efﬁcacy measures were the Brief
Pain Inventory (BPI) 24-h average pain severity score (0–10), and
the Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC;0–96). Missing data were imputed using last-observation-
carried-forward method. Differences in treatment effect of duloxetine
versus placebo between subgroups were analyzed with an ANCOVA
model that included therapy, study, baseline value, concomitant NSAID
use, and therapy-by-NSAID subgroup interaction. Safety and tolerability
were assessed with spontaneously reported treatment-emergent adverse
events (TEAEs).
Results: There were a total of 105 duloxetine NSAID users, 112
placebo NSAID users, 134 duloxetine non-NSAID users, and 136 placebo
non-NSAID users. Overall mean baseline ratings were BPI average
pain=6.15, and WOMAC total=51.37, and there were no signiﬁcant
differences between NSAID subgroups on these measures. Mean changes
from baseline are summarized in Figure 1. Treatment-by-NSAID use
interactions were not signiﬁcant for either of the outcome measures,
which suggests that the effect of duloxetine treatment was not affected
by concomitant NSAID use. Nausea was the most common TEAE reported
in patients treated with duloxetine vs. placebo that was signiﬁcantly
(p < 0.05) more frequent regardless of concomitant NSAID use. In addition
among NSAID users, patients treated with duloxetine vs. placebo reported
signiﬁcantly more hyperhidrosis (p < 0.05); and constipation (p < 0.01)
was reported signiﬁcantly more frequently among the non-NSAID users.
Fig. 1. Mean changes from baseline in BPI average pain severity and
WOMAC total.
Conclusions: There were a total of 105 duloxetine NSAID users, 112
placebo NSAID users, 134 duloxetine non-NSAID users, and 136 placebo
non-NSAID users. Overall mean baseline ratings were BPI average
pain=6.15, and WOMAC total=51.37, and there were no signiﬁcant
differences between NSAID subgroups on these measures. Mean changes
from baseline are summarized in Figure 1. Treatment-by-NSAID use
interactions were not signiﬁcant for either of the outcome measures,
which suggests that the effect of duloxetine treatment was not affected
by concomitant NSAID use. Nausea was the most common TEAE reported
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in patients treated with duloxetine vs. placebo that was signiﬁcantly
(p < 0.05) more frequent regardless of concomitant NSAID use. In addition
among NSAID users, patients treated with duloxetine vs. placebo reported
signiﬁcantly more hyperhidrosis (p < 0.05); and constipation (p < 0.01)
was reported signiﬁcantly more frequently among the non-NSAID users.
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COMPARISON OF DIFFERENT EXPERIMENTAL DESIGNS TO EVALUATE
THE EFFICACY OF AN INTERVENTION IN OSTEOARTHRITIS PATIENTS
D. Martinez-Puig1, C. Chetrit1, I. Mo¨ller2. 1BIOIBERICA S.A., Palafolls,
Spain; 2Inst. Poal de Reumatologia, Barcelona, Spain
Purpose: The design of a clinical trial to test the efﬁcacy of an
intervention in osteoarthritis patients is strongly hampered by different
factors such as the absence of a fully validated biomarker, the magnitude
of the placebo effect and the enormous variability associated to the
clinical outcomes. The objective of this study is to compare the validity
and usefulness of different clinical trial designs to test the efﬁcacy and
safety of a food supplement for the management of knee osteoarthritis.
Methods: In order to study the effect of the trial design on the
results achieved, 2 clinical trials testing the same product for the
management of osteoarthritis (Hyal-Joint®, Bioiberica, Spain), have been
compared. The ﬁrst clinical trial (n = 71) used retrospective data from
consecutive patients fulﬁlling inclusion criteria (moderate to severe
knee OA coursing with synovitis) who were treated with Hyal-Joint
(80mg/d) or acetaminophen (500mg/d). The second trial used the same
sample size (n = 70) and same inclusion criteria, but the study was
prospective and compared the treatment with Hyal-Joint (80mg/d) or
with placebo (80mg/d) in a double-blind design. Progression of pain
intensity (Huskisson’s VAS) has been used as one of the clinical outcomes
in both trials. Data from a subsequent prospective double-blind placebo-
controlled clinical trial (n = 40) using alternative clinical outcomes has
also been discussed. In this trial, instead of using traditional clinical
outcomes such as pain perception, joint function was evaluated using
standard isokinetic assessment (Biodex system 3 for measuring maximal
muscle strength, total work and power mean).
Results: Results from the retrospective trial showed a 49.1% pain
reduction from basal values after 3 months of treatment with Hyal-Joint,
while the reduction associated to the treatment with acetaminophen was
only of 23.1%. Differences between treatment groups were statistically
signiﬁcant (P < 0.05). Results from the prospective trial showed the
same pain reduction from the basal values associated to the treatment
with Hyal-Joint during 3 months (47.9%), but the reduction associated
to the placebo treatment was of 39.6%, and differences between
treatments groups only tended to reach statistical signiﬁcance (P > 0.05).
Interestingly, the pain relief associated to the placebo treatment
is statistically higher than pain relief associated to acetaminophen
(P < 0.05). On the subsequent clinical trial, statistically signiﬁcant
improvements were obtained compared to the placebo group even using
a lower sample size (n = 40). The increase of the maximum peak torque
of the knee extensors at 3 months compared to baseline was 6.5±5.8 Nm
for the active group and −1.0±7.1 Nm for the placebo group at 240°/s
(P < 0.05). The same pattern of response was obtained for total work
(P = 0.0588) and power mean (P < 0.05).
Conclusions: The overall results show that variability of traditional
clinical outcomes and the size of the placebo effect could difﬁcult the
obtaining of statistical results in osteoarthritis trials. According to the
results, one possible strategy to overcome these handicaps could be the
use of purely objective data such as the isokinetic assessment of the
affected joint.
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LONG-TERM EFFICACY OF SEQUENTIALLY PROGRAMMED MAGNETIC
FIELD (SPMF) THERAPY IN PATIENTS WITH OSTEOARTHRITIS OF
THE KNEE
V.G. Vasishta. SBF Hlth.care & Res. Ctr. Pvt.Ltd., Bangalore, India
Purpose: A study to demonstrate the efﬁcacy of SPMF therapy on
195 patients (390 knees) with clinically and radiologically conﬁrmed
osteoarthritis (OA) of the knee, was published in the Scientiﬁc Medicine
journal in 2009. The results showed an increase in cartilage thickness
measured using MRI at three months follow-up compared to pre-
treatment values. The present follow-up study was conducted, using
the Knee Society clinical rating system, to demonstrate the long-term
efﬁcacy of SPMF, on varying grades of severity of OA.
Methods: This study was designed to be a prospective non-randomised
clinical evaluation of SPMF therapy.
SPMFs are non-thermal and non-ionising electromagnetic ﬁelds, working
on the principle of altering cell membrane potential by generating piezo-
electric stimulus, resulting in cartilage and bone regeneration. When
these ﬁelds are precisely focused on the tissues, they aid in regeneration
of cartilage by the ampliﬁcation of IGF-1, synthesis of proteoglycan,
normalisation of the electromagnetic ﬁleds in and around the Centrioles,
and ‘up-regulation’ of HSR/HSF-1 pathways.
175 patients aged 30 years and above, with Grade III/IV OA (Kellgren &
Lawrence grading system) of the knee, who had undergone SPMF therapy
9 months earlier were enrolled after obtaining their written consent.
The 9-month follow-up data were collected along the lines of previously
collated pre-treatment and follow-up data. The main outcome measures
included differences in pre-treatment parameters compared to the
outcomes after SPMF therapy at intervals of 21 days, and 3 months
and 9 months after completion of the therapy. Additionally, adverse
effects to treatment were also recorded at 9-month follow-up.
Results: Statistical analysis of the collected data demonstrated an
improvement in TFS scores from 39.64 (SD=21.53) pre-treatment to
47.84 (SD=18.54) at 21 days, 56.92 (SD=16.47) at 3 months, and 61.20
(SD=16.63) at 9 months follow-up.
The TKS score was 53.08 (SD=17.39) at pre-treatment, which improved
to 73.44 (SD=13.61), 78.64 (SD=12.26), and 83.32 (SD=11.63) at 21 days,
3 months, and 9 months, respectively.
Participants with grade III OA showed an improvement in TFS from a pre-
treatment score of 48.50 (SD=33.46) to scores of 57.25 (SD=23.25), 65.13
(SD=21.02), and 71.62 (SD=20.13) at 21 days, 3 months, and 9 months,
respectively. For grade IV OA, the TFS score of 35.47 (SD=12.15) pre-
treatment, improved to 43.41 (SD=14.63), 53.06 (SD=12.80), and 56.29
(SD=12.55) at 21 days, 3 months, and 9 months follow-up, respectively.
TKS scores for grade III OA improved from 63.63 (SD=23.08) pre-
treatment, to 78.62 (SD=13.39), 83.87 (SD=12.83) and 87.50 (SD=14.28)
at 21 days, 3 months, and 9 months follow-up, respectively. Similarly,
the TKS scores for grade IV OA increased from 48.12 (SD=11.78) pre-
treatment to 71.00 (SD=13.39), 76.17 (SD=11.55), and 81.35 (SD=10.04)
at 21 days, 3 months and 9 months, respectively.
Conclusions: This study proves that SPMF therapy is an effective
treatment modality for OA of the knee, as demonstrated through
signiﬁcant improvements in TKS and TFS scores at 21 days, 3 months and
these scores are maintained over the follow up period of 9 months. In
addition, the study also provides evidence to indicate that SPMF therapy
improves outcomes in all grades of OA. This therapy should be a ﬁrst line
of treatment for OA due to its non-invasive nature, long term efﬁcacy
and since it can be provided on an out-patient basis.
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THE PRELIMINARY REPORT OF ENHANCED ROLE OF PLATELET-RICH
PLASMA (PRP) WITH ARTHROSCOPIC MICROFRACTURE IN
EARLY-STAGED OSTEOARTHRITIS OF KNEE
J-D. Kim, G. Lee, G-H. Jung. Kosin Univ. Gospel Hosp., Busan, Korea,
Republic of
Purpose: Platelet-Rich Plasma (PRP) is a natural concentrate of
autologous blood growth factors experimented in different ﬁelds of
medicine in order to test its potential to enhance tissue regeneration, and
so was emerged as a treatment option for tendinopathies and chronic
wounds. In addition to release of growth factors, PRP also promotes
concentrated anti-inﬂammatory signals including interleukin-1a, which
has been known to be a focus of emerging treatments for osteoarthritis.
In cartilage defect of knee, arthroscopic microfracture is the most widely
utilized cartilage restoration technique worldwide, and the results for
most osteoarthritis patients are good, especially in the short term.
However, according to many reports about this technique, the results
of arthroscopic microfracture were not good in the patients of larger
defects (>4 cm2), older patients (age >40 years), and these factors likely
inﬂuence on an overall observation that the results of microfracture tend
to deteriorate over time, particularly after 2 years. Our authors suggested
that the tissue-regenerative property of PRP can be helpful for enhancing
the effect of the microfracture, but no references about this theory were
found. The primary objective is to study the application of PRP with
